Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Options GDR Silver Project, Silvertip-Midway District, Yukon (click to learn more) Ciscom Corp. Strengthens Its Board of Directors with Addition of Two Experienced Industry Leaders (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Pharmadrug Inc C.PHRX

Alternate Symbol(s):  LMLLF

Medical Care Cannabis
PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases (including Covid-19) and rare cancers. In clinical research, Cepharanthine exhibits multiple pharmacological effects, including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions.


CSE:PHRX - Post by User

Pharmadrug Inc > Whats Expected .
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Comment by ScotiaOneon Jan 11, 2021 8:47pm
82 Views
Post# 32272987

RE:RE:RE:RE:Whats Expected .

RE:RE:RE:RE:Whats Expected . Agreed, I'm putting my chips on a positive announcement. 50/50 right so why not lean to the bright side!  Good luck tomorrow everyone.

FreeDom789 wrote:

Take a look at their latest NR from Dec.15th  Seems to fit nicely with this halt doesn't it! We'll see soon enough! GLTA 

https://ca.finance.yahoo.com/news/pharmadrug-provides-corporate-balance-sheet-133800751.html



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities